12/08/2025
Today (12/8), we’re proud to share that our 11th peer-reviewed study on the Asqelio™ Trifocal intraocular lens (IOL) has just been published in the Clinical Ophthalmology (2025, v19, pp 4481-4491).
The study was conducted to compare six-month refractive accuracy, visual performance, and patient-reported outcomes of a bi-aspheric trifocal intraocular lens (IOL) in Asian and European patients.
Results have shown that both groups achieved near-emmetropic outcomes, with 98% of Spanish and 80% of Taiwanese eyes within ±0.50 D of target refraction. Spanish eyes showed significantly lower residual astigmatism (–0.11 ± 0.20 D) than Taiwanese eyes (–0.72 ± 0.41 D; p < 0.001), corresponding to superior monocular and binocular acuities at distance, intermediate, and near. Despite this, Taiwanese patients reported comparable or higher satisfaction scores, suggesting cultural factors and visual demands affect perceived quality of vision. Contrast sensitivity for both cohorts fell within or above normative ranges, with minor losses at higher spatial frequencies under mesopic glare.
The paper concluded that the bi-aspheric Asqelio™ Trifocal IOL delivers excellent refractive and functional results in both Asian and European eyes. The divergence between objective metrics and patient-reported satisfaction underlines the necessity of including subjective outcomes in multifocal IOL assessments.
This publication reinforces the strong evidence base supporting Asqelio™ Trifocal as a reliable option for both cataract and refractive patients.
We’re deeply grateful to all the doctors, researchers, and hospital staff who made this study possible. Their dedication continues to inspire us to keep moving forward, staying true to our mission:
‘Making Happy Patients, One-by-One.’
https://doi.org/10.2147/OPTH.S571306
